Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.41 - $0.91 $43,885 - $97,404
-107,038 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$0.79 - $1.59 $1,657 - $3,335
-2,098 Reduced 1.92%
107,038 $89,000
Q4 2021

Feb 10, 2022

SELL
$1.36 - $2.94 $2,598 - $5,618
-1,911 Reduced 1.72%
109,136 $148,000
Q3 2021

Nov 12, 2021

SELL
$2.97 - $4.84 $12,471 - $20,323
-4,199 Reduced 3.64%
111,047 $334,000
Q2 2021

Aug 05, 2021

BUY
$3.71 - $5.13 $59,853 - $82,762
16,133 Added 16.28%
115,246 $532,000
Q1 2021

May 06, 2021

SELL
$4.08 - $14.75 $807 - $2,920
-198 Reduced 0.2%
99,113 $426,000
Q4 2020

Feb 10, 2021

BUY
$11.06 - $14.01 $65,331 - $82,757
5,907 Added 6.32%
99,311 $1.1 Million
Q3 2020

Nov 12, 2020

SELL
$10.26 - $14.55 $229,546 - $325,527
-22,373 Reduced 19.32%
93,404 $1.13 Million
Q2 2020

Aug 13, 2020

BUY
$7.11 - $13.76 $161,141 - $311,856
22,664 Added 24.34%
115,777 $1.59 Million
Q1 2020

May 06, 2020

BUY
$5.71 - $15.85 $32,238 - $89,489
5,646 Added 6.46%
93,113 $721,000
Q4 2019

Feb 05, 2020

BUY
$9.6 - $17.75 $17,913 - $33,121
1,866 Added 2.18%
87,467 $1.34 Million
Q3 2019

Oct 23, 2019

BUY
$12.16 - $21.0 $112,504 - $194,292
9,252 Added 12.12%
85,601 $1.04 Million
Q2 2019

Aug 14, 2019

BUY
$9.44 - $19.8 $191,849 - $402,395
20,323 Added 36.27%
76,349 $1.51 Million
Q1 2019

May 01, 2019

SELL
$11.11 - $13.49 $5,321 - $6,461
-479 Reduced 0.85%
56,026 $686,000
Q4 2018

Jan 31, 2019

BUY
$10.24 - $15.49 $197,345 - $298,523
19,272 Added 51.76%
56,505 $717,000
Q3 2018

Nov 07, 2018

SELL
$15.53 - $19.97 $29,631 - $38,102
-1,908 Reduced 4.87%
37,233 $579,000
Q2 2018

Aug 06, 2018

BUY
$15.88 - $19.5 $621,559 - $763,249
39,141 New
39,141 $730,000

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.